TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31334298

Group type: EXPERIMENTAL
Intervention: Preemptive switch to efavirenz (EFV)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: LPV/r with second-line option
Number of subjects: 2

Group type: COMPARATOR
Intervention: Continued LPV/r
Number of subjects: 2
Study: 31334480

Group type: EXPERIMENTAL
Intervention: Peer counseling combined with psychosocial stimulation (PC + PCS)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 350
Study: 31334546

Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (FSH) stimulation with a flexible antagonist protocol
Number of subjects: 22
Study: 31334596

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks
Number of subjects: 688

Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Mixture TGD model-based measures of tumor response
Number of subjects: 688
Study: 31334635

Group type: EXPERIMENTAL
Intervention: AB680, a potent human CD73 inhibitor
Number of subjects: 0
Study: 31334704

Group type: EXPERIMENTAL
Intervention: One-month dual antiplatelet therapy (DAPT)
Number of subjects: 858
Study: 31334762

Group type: COMPARATOR
Intervention: Low latent height class (LHC) in boys
Number of subjects: 536

Group type: COMPARATOR
Intervention: High latent height class (LHC) in boys
Number of subjects: 536
Study: 31334925

Group type: EXPERIMENTAL
Intervention: Topical collagen powder
Number of subjects: 8

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 8
Study: 31335117

Group type: EXPERIMENTAL
Intervention: NIR photoimmunotherapy (NIR-PIT) using IRdye700DX conjugated with a monoclonal antibody targeting cancer cell surface antigens.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIR photoimmunotherapy (NIR-PIT)
Number of subjects: 0
Study: 31335283

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography with fractional flow reserve analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31335321

Group type: EXPERIMENTAL
Intervention: CAR-T therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: ASCT
Number of subjects: 56
Study: 31335773

Group type: EXPERIMENTAL
Intervention: Perfluorobutane Microsphere-Enhanced Ultrasound
Number of subjects: 0
Study: 31336587

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-Lymphocyte Ratio (NLR) in delirious patients
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Early-onset delirium incidence
Number of subjects: 1001
Study: 31337344

Group type: EXPERIMENTAL
Intervention: Fluad® (adjuvanted inactivated trivalent influenza vaccine)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fluad®
Number of subjects: 200
Study: 31337428

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FDG-PET/MRI
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 31338061

Group type: EXPERIMENTAL
Intervention: TARGET® Intracranial Aneurysm Coiling
Number of subjects: 0
Study: 31338476

Group type: EXPERIMENTAL
Intervention: Nabilone (0.5-2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31338480

Group type: EXPERIMENTAL
Intervention: Classroom Communication Resource (CCR)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 454
Study: 31338660

Group type: COMPARATOR
Intervention: Controlled group (CGE-DC: controlled)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Not-controlled group (CGE-DC: not controlled)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Treatment-naïve patients
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Overall disease control evaluation
Number of subjects: 228
Study: 31338800

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 15 mg every 12 hours (q12h) for 5 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30 mg every 12 hours (q12h) for 5 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg every 12 hours (q12h) for 5 days
Number of subjects: 70
Study: 31339003

Group type: EXPERIMENTAL
Intervention: Percutaneous CT-guided cryovagotomy
Number of subjects: 20
Study: 31340773

Group type: EXPERIMENTAL
Intervention: High baseline Tie1 levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: High baseline Tie1 and Ang2 levels
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Baseline Ang2 levels
Number of subjects: 65
Study: 31340825

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation responders
Number of subjects: 92
Study: 31340870

Group type: EXPERIMENTAL
Intervention: Highest quintile of total dietary fibre intake (compared to lowest quintile)
Number of subjects: 35380
Study: 31340868

Group type: EXPERIMENTAL
Intervention: Sublingual microcirculation parameters in septic patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In vitro AFM data
Number of subjects: 40
Study: 31340872

Group type: EXPERIMENTAL
Intervention: Low-satiety phenotype (LSP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: High-satiety phenotype (HSP)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-satiety phenotype (LSP) under high energy-density (HED) conditions
Number of subjects: 96
Study: 31340965

Group type: EXPERIMENTAL
Intervention: Primary dual marker strategy (DMS) discharge group
Number of subjects: 2294

Group type: COMPARATOR
Intervention: Conventional workup group
Number of subjects: 2294
Study: 31340982

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg twice daily
Number of subjects: 144

Group type: COMPARATOR
Intervention: Zanubrutinib 320 mg once daily
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Zanubrutinib (various doses: 40, 80, 160, or 320 mg once daily or 160 mg twice daily)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 144
Study: 31341158

Group type: EXPERIMENTAL
Intervention: Test cohort (n=98)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Replication cohort (n=131)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Diagnostic biomarker based on GM volume pattern
Number of subjects: 329

Group type: COMPARATOR
Intervention: Healthy controls (n=66)
Number of subjects: 329
Study: 31341663

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31342318

Group type: EXPERIMENTAL
Intervention: Cognitive decline on personalized test selection
Number of subjects: 25

Group type: COMPARATOR
Intervention: Stable performance
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cognitive decline
Number of subjects: 25
Study: 31342473

Group type: EXPERIMENTAL
Intervention: BougieCap (Ovesco Endoscopy AG)
Number of subjects: 50
Study: 31342533

Group type: EXPERIMENTAL
Intervention: 8-week web-based individualised exercise program
Number of subjects: 44
Study: 31342832

Group type: EXPERIMENTAL
Intervention: Subcortical DWI lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Within-lesion heterogeneity analysis
Number of subjects: 0
Study: 31342851

Group type: EXPERIMENTAL
Intervention: Home-based telemental health therapy
Number of subjects: 0
Study: 31342904

Group type: EXPERIMENTAL
Intervention: CBT-i Coach mobile app intervention
Number of subjects: 38
Study: 31343500

Group type: EXPERIMENTAL
Intervention: Knee extensor strength in women with radiographic knee osteoarthritis (mean = -17.6 N)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Knee extensor strength in controls (mean = +4.5 N)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Knee extensor strength in women without radiographic knee osteoarthritis
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Change in extensor strength before incident pain
Number of subjects: 641
Study: 31343665

Group type: EXPERIMENTAL
Intervention: Nivolumab (0.1-10.0 mg/kg) every 2 weeks in 8-week cycles for up to 96 weeks
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with treatment-related AEs of any grade
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with treatment-related AEs of grade 3 or more
Number of subjects: 270

Group type: COMPARATOR
Intervention: Nivolumab treatment without treatment-related AEs
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with Eastern Cooperative Oncology Group performance status of 0
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with liver metastases
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nivolumab treatment with bone metastases
Number of subjects: 270
Study: 31344312

Group type: EXPERIMENTAL
Intervention: Presence of aquagenic pruritus (AP) in ET patients
Number of subjects: 396
Study: 31344674

Group type: EXPERIMENTAL
Intervention: IntelliCare mental health apps, 7-week intervention, with a 30-min coaching call before use and a 10-min follow-up coaching call 3 weeks later.
Number of subjects: 50
Study: 31344678

Group type: EXPERIMENTAL
Intervention: Haptic feedback in a virtual reality game intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (typically developing children)
Number of subjects: 34
Study: 31345012

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily until disease progression
Number of subjects: 66
Study: 31345133

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid filtration (neurapheresis therapy) for up to 24 hours
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid filtration (neurapheresis therapy)
Number of subjects: 13
Study: 31345207

Group type: EXPERIMENTAL
Intervention: Focused cardiac ultrasound (FCU) performed by general practitioners (GPs)/GP registrars after a training programme comprising 20 supervised FCU examinations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional cardiac ultrasound by specialists
Number of subjects: 100
Study: 31345240

Group type: EXPERIMENTAL
Intervention: CSM group (surgery)
Number of subjects: 24
Study: 31345639

Group type: EXPERIMENTAL
Intervention: 1 dose of MMR-containing vaccine (Priorix or Priorix-Tetra)
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: 2 doses of MMR-containing vaccine (Priorix or Priorix-Tetra)
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Second dose of MMR vaccine given later in life
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Second dose of MMR vaccine given anytime over the 10-year period
Number of subjects: 1887
Study: 31345776

Group type: EXPERIMENTAL
Intervention: MARD
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: MOD
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: SAID
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: SIRD
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: SIDD
Number of subjects: 1105
Study: 31345970

Group type: EXPERIMENTAL
Intervention: Known atrial fibrillation (AF) patients not treated with oral anticoagulation
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Newly diagnosed atrial fibrillation (AF) patients
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Patients with known AF
Number of subjects: 1470
Study: 31346584

Group type: EXPERIMENTAL
Intervention: A&T intensive (A&T-I) areas with specialized IYCF training, job aids, and regular supportive supervision
Number of subjects: 0

Group type: COMPARATOR
Intervention: A&T non-intensive (A&T-NI) areas with standard government training and supervision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLW-level performance outcomes
Number of subjects: 0
Study: 31346927

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus erlotinib
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg plus erlotinib
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus erlotinib
Number of subjects: 14

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus crizotinib
Number of subjects: 14

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Erlotinib plus ipilimumab
Number of subjects: 14
Study: 31346932

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 62
Study: 31346977

Group type: EXPERIMENTAL
Intervention: OdySight visual acuity module
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: OdySight contrast sensitivity module
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: OdySight Amsler Grid module
Number of subjects: 120
Study: 31347100

Group type: EXPERIMENTAL
Intervention: IDegLira (fixed-ratio combination of insulin degludec and liraglutide)
Number of subjects: 62

Group type: COMPARATOR
Intervention: MDI (multiple daily injections of insulin)
Number of subjects: 62
Study: 31347926

Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31348866

Group type: EXPERIMENTAL
Intervention: Surgical lysis of adhesions and manipulation under anesthesia for LOM after ACL reconstruction
Number of subjects: 58

Group type: COMPARATOR
Intervention: Matched controls without LOM
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Surgical treatment for LOM after ACL reconstruction
Number of subjects: 58
Study: 31348987

Group type: EXPERIMENTAL
Intervention: Dance/Movement Therapy
Number of subjects: 0
Study: 31349390

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosentan or macitentan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil (postoperative use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General PAH pharmacotherapy
Number of subjects: 0
Study: 31349844

Group type: EXPERIMENTAL
Intervention: Shared Decision Making and Renal Supportive Care (SDM-RSC) intervention
Number of subjects: 102
Study: 31349866

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg oral dispersible tablet)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo (identical to zinc tablet)
Number of subjects: 250
Study: 31350082

Group type: EXPERIMENTAL
Intervention: Bioinductive collagen implant for rotator cuff repair
Number of subjects: 0
Study: 31350159

Group type: EXPERIMENTAL
Intervention: Nutrition-related knowledge score assessed by the modified General Nutrition Knowledge Questionnaire (0-56 points)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: General dietary recommendations and dietary behaviors to reduce cardiovascular disease and cancer
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Health problems related to lower intake of fruit, vegetables, and fiber; knowledge about antioxidants vitamins
Number of subjects: 116
Study: 31350201

Group type: EXPERIMENTAL
Intervention: Capecitabine/Oxaliplatin regimen (capecitabine 825 mg/m2) with concurrent radiotherapy (RT)
Number of subjects: 20
Study: 31350241

Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during the periconception period and pregnancy.
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Safer conception strategies offered as part of the woman-centred programme.
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Clinical outcomes measured include HIV seroconversion rates and pregnancy and infant outcomes.
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Qualitative interviews conducted with participants.
Number of subjects: 350
Study: 31350244

Group type: EXPERIMENTAL
Intervention: SCD assessment including clinical and neuropsychological assessments, blood sample collection for plasma beta-amyloid and ApoE genotype, urine samples collection for AD7c-NTP, multimodal MRI scans, glucose metabolism and amyloid positron emission tomography.
Number of subjects: 800
Study: 31350251

Group type: EXPERIMENTAL
Intervention: Quality of Life in Adult Cancer Survivors; EORTC-QLQ-C30
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: EuroQol-5 dimensions (EQ-5D)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Self-efficacy, social support, social networks, and lifestyle questionnaires
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Clinical data
Number of subjects: 3000
Study: 31350306

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) monotherapy (1.8 mg/kg IV every 3 weeks up to 8 cycles)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) monotherapy
Number of subjects: 10
Study: 31350329

Group type: EXPERIMENTAL
Intervention: Sirolimus (56-day course)
Number of subjects: 18
Study: 31350784

Group type: EXPERIMENTAL
Intervention: Placebo effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocebo effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectancy violation
Number of subjects: 0
Study: 31351076

Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation (MI-E) titration
Number of subjects: 27
Study: 31351210

Group type: EXPERIMENTAL
Intervention: Super selective intra-arterial cerebral infusion (SIACI) of bevacizumab
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of bevacizumab
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Temozolomide with an investigational agent
Number of subjects: 1
Study: 31351267

Group type: EXPERIMENTAL
Intervention: Recommended targeted treatment (RTT)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Molecular profiling
Number of subjects: 309
Study: 31351371

Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 45
Study: 31351452

Group type: EXPERIMENTAL
Intervention: General anesthesia with low tidal volume ventilation and additional regional anesthesia (for abdominal surgery)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: General anesthesia with low tidal volume ventilation (for peripheral surgery)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Abdominal surgery
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Peripheral surgery
Number of subjects: 69
Study: 31351862

Group type: EXPERIMENTAL
Intervention: AMP-224 with SBRT (8 Gy on day 0) and cyclophosphamide (200 mg/m2)
Number of subjects: 15
Study: 31351922

Group type: EXPERIMENTAL
Intervention: 0.67 mg GLS-5300
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2 mg GLS-5300
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 6 mg GLS-5300
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All doses of GLS-5300
Number of subjects: 75
Study: 31352035

Group type: EXPERIMENTAL
Intervention: Dlco percent predicted decrease (continuous variable)
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Categorized severe impairment in Dlco
Number of subjects: 1806
Study: 31352417

Group type: EXPERIMENTAL
Intervention: Automated quantification of cardiovascular calcifications on planning CT scans
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Case-cohort analysis among cohort members diagnosed with a CVD event during follow-up (n≈200) and a random sample of the baseline cohort (n≈600)
Number of subjects: 16000
Study: 31352425

Group type: EXPERIMENTAL
Intervention: ePIPAC-OX (92 mg/m²)
Number of subjects: 0
Study: 31352486

Group type: EXPERIMENTAL
Intervention: E-cigarette use for 7 days followed by 6 days of abstinence
Number of subjects: 109
Study: 31352850

Group type: EXPERIMENTAL
Intervention: Plerixafor with rituximab
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rituximab 375 mg/m2
Number of subjects: 24
Study: 31353243

Group type: EXPERIMENTAL
Intervention: glecaprevir-pibrentasvir
Number of subjects: 25

Group type: COMPARATOR
Intervention: NAT-negative grafts
Number of subjects: 25
Study: 31353421

Group type: EXPERIMENTAL
Intervention: Biologic exposure (ratio of time on biologic relative to time in BRASS cohort)
Number of subjects: 1395
Study: 31353854

Group type: COMPARATOR
Intervention: microRNA expression analysis in serum of AOPD patients
Number of subjects: 50
Study: 31353964

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31354330

Group type: EXPERIMENTAL
Intervention: Hydrocortisone self-administration
Number of subjects: 0
Study: 31354810

Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metformin (1500 mg/daily) plus placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplements
Number of subjects: 40
Study: 31354960

Group type: EXPERIMENTAL
Intervention: Personalized eHealth intervention with daily goals via ExSed application for 90 days after discharge.
Number of subjects: 540

Group type: COMPARATOR
Intervention: Standard postsurgical rehabilitation guidance.
Number of subjects: 540
Study: 31355009

Group type: EXPERIMENTAL
Intervention: Easy Sleep Apnea Predictor (ESAP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Neck circumference
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) testing
Number of subjects: 43
Study: 31355176

Group type: EXPERIMENTAL
Intervention: Undernutrition assessment
Number of subjects: 0
Study: 31355205

Group type: EXPERIMENTAL
Intervention: AXA2678
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 31355467

Group type: EXPERIMENTAL
Intervention: Pevonedistat alone
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with azacitidine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with docetaxel
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with carboplatin + paclitaxel
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with gemcitabine
Number of subjects: 335
Study: 31355926

Group type: EXPERIMENTAL
Intervention: Satisfactory AFP decline (AFP normalized within the first 2 measures after chemotherapy)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Unsatisfactory AFP decline (AFP half-life >7 days after chemotherapy)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patients aged 11 years or older with standard risk 2 disease
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patients with satisfactory decline vs unsatisfactory decline
Number of subjects: 131
Study: 31356140

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 125